Compare Snap Inc (SNAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Snap Inc trades at $4.58 (market cap $7.67B), while Vertex Pharmaceuticals Incorporated trades at $478.01 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 15.9× Snap Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| SNAP | VRTX | |
|---|---|---|
Market Cap | $7.67B | $121.95B |
Sector | Media | Health |
52-Week High | $10.35 | $529.59 |
52-Week Low | $3.93 | $366.54 |
Enterprise Value | $9.05B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $4.56, up 0.77% on the day, with a bearish technical signal and mixed fundamentals. Revenue grew to $5.93B in 2025, but net losses persist at -$460M. The stock shows improving cash flow from operations and has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $5.83 price target, suggesting modest upside from current levels.
The outlook remains cautious due to ongoing losses and competitive pressures, though cost-cutting and AR initiatives offer potential. Key risks include high debt, regulatory scrutiny, and uncertain demand for new products like SPECS glasses. Upside depends on sustained user engagement and profitability improvements.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
